Sanders Williams - Amgen Insider

Amgen Inc -- USA Stock  

USD 170.12  0.16  0.0941%

Independent Director

Dr. R. Sanders Williams, M.D., is an Independent Director of Amgen Inc. R. Sanders Williams is President of Gladstone Institutes, a nonprofit biomedical research enterprise, and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, both since 2010. He is also a Professor of Medicine at the University of California, San Francisco since 2010. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the DukeNUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center. Dr. Williams was a director of the Laboratory Corporationrationration of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of BristolMyers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a nonprofit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a nonprofit science museum and learning center located in San Francisco, since 2011. Dr. Williams was elected to the National Academy of Medicine in 2002
Age: 67  Director Since 2014      
805 447-1010  www.amgen.com
Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Fred WeissAllergan plc
2013
William YoungVertex Pharmaceuticals Incorpor
2014
Alan GarberVertex Pharmaceuticals Incorpor
2017
Louis DrapeauBio Rad Laboratories Inc
2007
William MontagueEndo International plc
2009
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Catherine KlemaAllergan plc
2016
Sharad MansukaniEndo International plc
2017
Christopher CoughlinAllergan plc
2016
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Robert AlpernAbbott Laboratories
2008
Peter McDonnellAllergan plc
2015
David AltshulerVertex Pharmaceuticals Incorpor
2015
Daniel StarksAbbott Laboratories
2017
Robert MalchioneBio Rad Laboratories Inc
2014
W FarrellAbbott Laboratories
2006
Joel McCombBio Rad Laboratories Inc
2014
Deborah NeffBio Rad Laboratories Inc
2011
Michael HyattEndo International plc
N/A
Ron TaylorAllergan plc
2013
Elaine UllianVertex Pharmaceuticals Incorpor
2011

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Volatility Now
   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
Hide  View All  NextLaunch Portfolio Volatility
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators